[33F2-33F2];[34A5-34A5];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
33F2;34A5
Breakpoint based on release 3 sequence coordinate from Thibault et al., 2004, Supplementary Table 2 (FBrf0174227) or 3 (FBrf0174228), converted to release 5 coordinate.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Lethal in combination with Df(2L)Exel6034.
Fails to complement Df(2L)ED778.
Inferred to overlap with: Df(2L)ED778.
The presence of P+PBac{XP5.WH5}BSC290 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d08229 to be at Release 3 genomic coordinate 13049022 on chromosome arm 2L. This corresponds to 34A5 on the Release 5 genome map. The predicted position of PBac{WH}f02059 on the Release 5 map is 33F2 . Consequently, the cytological breakpoints of Df(2L)BSC290 are predicted to be 33F2;34A5.